<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39482691</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6963</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>BMC health services research</Title><ISOAbbreviation>BMC Health Serv Res</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-COVID-19 condition after hospitalisation for COVID-19: the REGAIN RCT.</ArticleTitle><Pagination><StartPage>1326</StartPage><MedlinePgn>1326</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1326</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12913-024-11679-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Following the COVID-19 pandemic, millions of people continue to experience ongoing physical and mental health sequelae after recovery from acute infection. There is currently no specific treatment for the diverse symptoms associated with post-COVID-19 condition. Physical and mental health rehabilitation may help improve quality of life in such patients. This study reports the cost-effectiveness of a programme of physical and mental health rehabilitation compared to best practice usual care in people with post-COVID-19 condition who were previously hospitalised.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted an economic evaluation within a randomised controlled trial from the perspective of the UK national health service (NHS) and personnel social services perspective (PSS). Resource used and health-related quality of life were collected using bespoke questionnaire and the EQ-5D-5&#xa0;L questionnaire at three, six, and 12 months. Incremental costs and quality adjusted life years accrued over the follow-up period were estimated and reported as the incremental cost-effectiveness ratio. Estimate uncertainty was managed by multiple imputation and bootstrapping cost-effectiveness estimates; and displayed graphically on the cost-effectiveness plane.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over a 12-month time horizon, incremental costs and QALYs were &#xa3;305 (95% CI: -123 to 732) and 0.026 (95% CI: -0.005 to 0.052) respectively. The ICER was &#xa3;11,941 per QALY indicating cost-effective care. Sensitivity analyses supported the base case findings. The probability of the intervention being cost-effective at a &#xa3;30,000 per QALY willingness-to-pay threshold was 84%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The within-trial economic evaluation suggested that people with post-COVID-19 condition after hospitalisation should be offered a programme of physical and mental health rehabilitation as it likely reflects a cost-effective use of NHS resources. Hospitalisation for COVID-19 has become less commonplace: further evaluation in non-hospitalised patients may be worthwhile.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ISRCTN registry ISRCTN11466448 23rd November 2020.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nwankwo</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK. henry.nwankwo@warwick.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Underwood</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruce</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lall</LastName><ForeName>Ranjit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratna</LastName><ForeName>Mariam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGregor</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute for Health and Wellbeing, Coventry University, Coventry, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NIHR132046</GrantID><Agency>National Institute for Health and Care Research</Agency><Country/></Grant><Grant><GrantID>NIHR132046</GrantID><Agency>National Institute for Health and Care Research</Agency><Country/></Grant><Grant><GrantID>NIHR132046</GrantID><Agency>National Institute for Health and Care Research</Agency><Country/></Grant><Grant><GrantID>NIHR132046</GrantID><Agency>National Institute for Health and Care Research</Agency><Country/></Grant><Grant><GrantID>NIHR132046</GrantID><Agency>National Institute for Health and Care Research</Agency><Country/></Grant><Grant><GrantID>NIHR132046</GrantID><Agency>National Institute for Health and Care Research</Agency><Country/></Grant><Grant><GrantID>NIHR132046</GrantID><Agency>National Institute for Health and Care Research</Agency><Country/></Grant><Grant><GrantID>NIHR132046</GrantID><Agency>National Institute for Health and Care Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Health Serv Res</MedlineTA><NlmUniqueID>101088677</NlmUniqueID><ISSNLinking>1472-6963</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="Y">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013222" MajorTopicYN="N">State Medicine</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cost-effectiveness analysis</Keyword><Keyword MajorTopicYN="N">Cost-utility analysis</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Mental health rehabilitation</Keyword><Keyword MajorTopicYN="N">Physical rehabilitation</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 condition</Keyword><Keyword MajorTopicYN="N">RCT</Keyword><Keyword MajorTopicYN="N">Randomised controlled trials</Keyword><Keyword MajorTopicYN="N">Rehabilitation</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39482691</ArticleId><ArticleId IdType="pmc">PMC11528998</ArticleId><ArticleId IdType="doi">10.1186/s12913-024-11679-5</ArticleId><ArticleId IdType="pii">10.1186/s12913-024-11679-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raveendran A, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metabolic Syndrome: Clin Res Reviews. 2021;15(3):869&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023. 2023 [cited 2024 14/02]; https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/30march2023.</Citation></Reference><Reference><Citation>UK Health Security Agency. COVID-19 Hospital Activity. 2024. [cited 2024 05/09]. Available from: https://ukhsa-dashboard.data.gov.uk/topics/covid-19.</Citation></Reference><Reference><Citation>Evans RA, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK Multicentre, prospective cohort study. Lancet Respiratory Med. 2021;9(11):1275&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney LL, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine. 2023;55:101762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha C, Baek G. Symptoms and management of long COVID: a scoping review. J Clin Nurs. 2024;33(1):11&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">34913540</ArticleId></ArticleIdList></Reference><Reference><Citation>Huizinga F, et al. Home-based physical activity to alleviate fatigue in cancer survivors: a systematic review and meta-analysis. Med Sci Sports Exerc. 2021;53(12):2661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8594505</ArticleId><ArticleId IdType="pubmed">34649267</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH. 2015 global survey on health technology assessment by national authorities: main findings, in 2015 global survey on health technology assessment by national authorities: main findings. 2015.</Citation></Reference><Reference><Citation>McGregor G, et al. Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial. BMJ. 2024;384:e076506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11134408</ArticleId><ArticleId IdType="pubmed">38325873</ArticleId></ArticleIdList></Reference><Reference><Citation>McGregor G, et al. Rehabilitation Exercise and psycholoGical support after covid-19 InfectioN&#x2019;(REGAIN): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785779</ArticleId><ArticleId IdType="pubmed">33407804</ArticleId></ArticleIdList></Reference><Reference><Citation>British National Formulary. British National Formulary. 2022;81. [cited 2022 01/12]. Available from: https://bnf.nice.org.uk/.</Citation></Reference><Reference><Citation>Ennis S, et al. Development of an online intervention for the Rehabilitation Exercise and psycholoGical support after covid-19 InfectioN (REGAIN) trial. NIHR Open Res. 2023;3:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10593321</ArticleId><ArticleId IdType="pubmed">37881468</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS Improvement, NHS Improvement. Highlights, analysis and introduction to the data, in 2021/22 National Cost Collection Data Publication, National Health Service England. 2022.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. 2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">27905712</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones KC, Weatherly H, Birch S, Castelli A, Chalkley M, Dargan A, Forder JE, Gao J, Hinde S, Markham S, Ogunleye D. Unit Costs of Health and Social Care 2022 Manual. Technical report. Personal Social Services Research Unit (University of Kent) &amp; Centre for Health Economics (University of York), Kent. 2023. 10.22024/UniKent/01.02.100519.</Citation></Reference><Reference><Citation>NHS Business Services Authority. Prescription Cost Analysis-England. 2022. [cited 2023 02/02]. Available from: https://www.nhsbsa.nhs.uk/statistical-collections/prescription-cost-analysis-england/prescription-cost-analysis-england-202122.</Citation></Reference><Reference><Citation>Office for National Statistics. Employee earnings in the UK: 2021. London: Office for National Statistics; 2021.</Citation></Reference><Reference><Citation>Herdman M, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hout B, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">22867780</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK Population Study. Pharmacoeconomics. 2023;41(2):199&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9883358</ArticleId><ArticleId IdType="pubmed">36449173</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. Position statement on use of the EQ-5D-5L value set for England (updated October. 2019). 2019; https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l.</Citation></Reference><Reference><Citation>Gomes M, et al. Multiple imputation methods for handling missing data in cost-effectiveness analyses that use data from hierarchical studies: an application to cluster randomized trials. Med Decis Making. 2013;33(8):1051&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">23913915</ArticleId></ArticleIdList></Reference><Reference><Citation>StataCorp. College Station, TX: StataCorp LP; 2023. Stata Stat Software: Release. 2023;19:19.</Citation></Reference><Reference><Citation>Faria R, et al. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics. 2014;32(12):1157&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4244574</ArticleId><ArticleId IdType="pubmed">25069632</ArticleId></ArticleIdList></Reference><Reference><Citation>Madley-Dowd P, et al. The proportion of missing data should not be used to guide decisions on multiple imputation. J Clin Epidemiol. 2019;110:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547017</ArticleId><ArticleId IdType="pubmed">30878639</ArticleId></ArticleIdList></Reference><Reference><Citation>Little RJ, Rubin DB. Statistical analysis with missing data, vol. 793. College Station: John Wiley &amp; Sons; 2019.</Citation></Reference><Reference><Citation>Grishechkina IA, Lobanov AA, Andronov SV, Rachin AP, Fesyun AD, Ivanova EP, Masiero S, Maccarone MC. Long-term outcomes of different rehabilitation programs in patients with long COVID syndrome: a cohort prospective study. Eur J Transl Myol. 2023;33(2):11063. 10.4081/ejtm.2023.11063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10388602</ArticleId><ArticleId IdType="pubmed">37052043</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopp S, et al. Outpatient pulmonary rehabilitation in patients with long COVID improves exercise capacity, functional status, dyspnea, fatigue, and quality of life. Respiration. 2022;101(6):593&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9059007</ArticleId><ArticleId IdType="pubmed">35203084</ArticleId></ArticleIdList></Reference><Reference><Citation>Compagno S, et al. Physical and psychological reconditioning in long COVID syndrome: results of an out-of-hospital exercise and psychological-based rehabilitation program. IJC Heart Vasculature. 2022;41:101080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9286763</ArticleId><ArticleId IdType="pubmed">35854691</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimeno-Almaz&#xe1;n A, et al. Rehabilitation for post-COVID-19 condition through a supervised exercise intervention: a randomized controlled trial. Scand J Med Sci Sports. 2022;32(12):1791&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538729</ArticleId><ArticleId IdType="pubmed">36111386</ArticleId></ArticleIdList></Reference><Reference><Citation>Longobardi I, et al. Effects of a 16-week home-based exercise training programme on health-related quality of life, functional capacity, and persistent symptoms in survivors of severe/critical COVID-19: a randomised controlled trial. Br J Sports Med. 2023;57(20):1295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">37164620</ArticleId></ArticleIdList></Reference><Reference><Citation>Berentschot JC, Heijenbrok-Kal MH, Bek LM, Huijts SM, van Bommel J, van Genderen ME, Aerts JGJV, Ribbers GM, Hellemons ME, van den Berg-Emons RJG; CO-FLOW Collaboration Group. Physical recovery across care pathways up to 12 months after hospitalization for COVID-19: A multicenter prospective cohort study (CO-FLOW). Lancet Reg Health Eur. 2022;22:100485. 10.1016/j.lanepe.2022.100485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9402257</ArticleId><ArticleId IdType="pubmed">36039177</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Garc&#xed;a JC, Reinoso-Cobo A, Piqueras-Sola B, Cort&#xe9;s-Mart&#xed;n J, Menor-Rodr&#xed;guez MJ, Alabau-Dasi R, Rodr&#xed;guez-Blanque R. Long COVID and Physical Therapy: a Systematic Review. Diseases. 2023;11(4):163. 10.3390/diseases11040163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10660729</ArticleId><ArticleId IdType="pubmed">37987274</ArticleId></ArticleIdList></Reference><Reference><Citation>Melendez-Oliva E, et al. Efficacy of pulmonary rehabilitation in post-COVID-19: a systematic review and meta-analysis. Biomedicines. 2023;11(8):2213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10452542</ArticleId><ArticleId IdType="pubmed">37626710</ArticleId></ArticleIdList></Reference><Reference><Citation>Erku D, Khatri R, Endalamaw A, Wolka E, Nigatu F, Zewdie A, Assefa Y. Digital Health Interventions to Improve Access to and Quality of Primary Health Care Services: a scoping review. Int J Environ Res Public Health. 2023;20(19):6854. 10.3390/ijerph20196854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10572344</ArticleId><ArticleId IdType="pubmed">37835125</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N, et al. Post-COVID-19: can digital solutions lead to a more equitable global healthcare workforce? BJPsych Int. 2023;20(1):18&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9909439</ArticleId><ArticleId IdType="pubmed">36812032</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical management of COVID-19: living guideline, 13 January 2023. Geneva: World Health Organization; 2023. (WHO/2019-nCoV/clinical/2023.1). Licence: CC BY-NC-SA 3.0 IGO.</Citation></Reference><Reference><Citation>Pichon-Riviere A, et al. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Global Health. 2023;11(6):e833&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">37202020</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators G. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The economic cost of long COVID: an update. Publish Online July; 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>